A cheap gout pill may prevent heart attacks and strokes, and doctors may not be prescribing enough of it.
That is the implication of a large new study published in JAMA Internal Medicine, which followed more than 109,000 gout patients in the UK over 14 years and found that those who lowered their uric acid sufficiently on allopurinol, the most common gout drug, had fewer major cardiovascular events than those who did not. The overall result was modest: a 9% reduction in heart attack, stroke, and cardiovascular death. But the numbers tell a different story when you look at how deeply patients lowered their uric acid. Patients who hit a serum urate level below 5 milligrams per deciliter, deeper than the current guideline target, saw their risk drop by 23%. The gradient is real, and it raises an uncomfortable question: are guidelines telling doctors to prescribe too little?
Gout is caused by uric acid crystals depositing in joints, triggering sudden and excruciating inflammation. It affects roughly 1 in 40 adults across the UK and EU and is associated with elevated cardiovascular risk, according to EurekAlert. The connection is not incidental. High uric acid appears to contribute to vascular inflammation, and gout patients face roughly double the heart attack risk of similar patients without the condition. Allopurinol works by blocking uric acid production at its source. The standard target, set by major clinical guidelines, is to reduce serum urate below 6 mg/dL, enough to dissolve existing crystals and prevent new flares.
The JAMA Internal Medicine study, led by Edoardo Cipolletta and colleagues under Prof. Abhishek at the University of Nottingham, used an emulated target trial framework with data from the Clinical Practice Research Datalink Aurum, following patients from 2007 to 2021. Of the 109,504 patients newly prescribed urate-lowering therapy, only 27.3% reached the guideline target within 12 months. Among those who did, getting their serum urate below 6 mg/dL, the hazard ratio for major adverse cardiovascular events was 0.91 compared to patients who never hit target. Modest, but real.
The dose-response data are what make this more than a footnote. Patients who achieved a lower serum urate target of less than 5 mg/dL had a weighted hazard ratio of 0.77, a substantially larger risk reduction, with a survival difference of 2.6 percentage points at five years. That gradient (the deeper you lower it, the more cardiovascular protection you get) is the finding the researchers emphasized. "This is the first study to find that medicines such as allopurinol that are used to treat gout reduce the risk of heart attack and stroke if they are taken at the right dose", Abhishek said in a statement.
The important caveat is that this is not a randomized trial. The study is observational, using methods designed to emulate a trial, but residual confounding cannot be ruled out. Patients who achieve lower serum urate may differ from those who do not in ways the study cannot fully measure, including overall health behaviors and adherence to other medications. Randomized data would settle the question; none yet exist.
The implications, if the finding holds, are large. Allopurinol is cheap. A month's supply costs roughly $4 to $15 without insurance in the US and has been generic for decades. Repurposing it as a cardiovascular intervention would require a large, costly randomized trial, and no such trial is currently funded or announced. The path from observational data to clinical guideline change typically takes years and requires replication. But the biological plausibility is there: uric acid drives vascular inflammation, and allopurinol has shown mixed but occasionally positive results in prior cardiovascular trials, particularly at higher doses. A 2020 paper in Annals of the Rheumatic Diseases noted that earlier trials may have used doses too low to detect benefit, consistent with what the new data suggest.
For founders and investors in cardiovascular or metabolic disease, the study is a reminder that the most commercially interesting drugs are not always the newest or most expensive. A generic that works better at higher doses, if validated, could be prescribed to millions of patients who currently receive inadequate doses and never reach target. That is a significant undertreatment problem, and an equally significant commercial opportunity for whoever funds the definitive trial.
The harder question is why so few patients hit target in the first place. Reaching serum urate below 6 mg/dL requires dose titration, monitoring, and patience. Many patients never get there. The new data suggest that failing to titrate aggressively enough may mean failing to capture the cardiovascular benefit entirely. If future trials confirm the dose-response, guideline committees will face pressure to revisit the targets, and prescribers will need to accept that more aggressive urate lowering is not just about joint pain, but about the heart.
